Drugs & Targets EC grants marketing authorization for Removab as a treatment for malignant ascites February 14, 2025Vol.51 No.06
Drugs & Targets Moffitt, 1ST Biotherapeutics collaborate to advance immuno-oncology February 14, 2025Vol.51 No.06
Drugs & Targets FDA grants orphan drug designation to MB-105 for CD5-targeted CAR T-cell therapy February 07, 2025Vol.51 No.05
Drugs & Targets CHMP recommends approval of Opdivo + Yervoy for unresectable or advanced HCC February 07, 2025Vol.51 No.05
Drugs & Targets CHMP recommends approval Breyanzi for r/r follicular lymphoma February 07, 2025Vol.51 No.05
Drugs & Targets FDA approves Enhertu as first HER2-directed therapy for breast cancer January 31, 2025Vol.51 No.04
Drugs & Targets FDA approves Grafapex as preparative regiment for allogeneic hematopoietic stem cell transplantation in AML or MDS January 31, 2025Vol.51 No.04
Drugs & Targets Yunu, WCG collaborate to support clinical trial imaging services January 31, 2025Vol.51 No.04
Drugs & Targets FDA grants RP1 BLA priority review for advanced melanoma January 24, 2025Vol.51 No.03
